Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.biomaterials.2006.09.044
DC Field | Value | |
---|---|---|
dc.title | In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma | |
dc.contributor.author | Kumar Naraharisetti, P. | |
dc.contributor.author | Yung Sheng Ong, B. | |
dc.contributor.author | Wei Xie, J. | |
dc.contributor.author | Kam Yiu Lee, T. | |
dc.contributor.author | Wang, C.-H. | |
dc.contributor.author | Sahinidis, N.V. | |
dc.date.accessioned | 2014-06-17T07:43:10Z | |
dc.date.available | 2014-06-17T07:43:10Z | |
dc.date.issued | 2007-02 | |
dc.identifier.citation | Kumar Naraharisetti, P., Yung Sheng Ong, B., Wei Xie, J., Kam Yiu Lee, T., Wang, C.-H., Sahinidis, N.V. (2007-02). In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma. Biomaterials 28 (5) : 886-894. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2006.09.044 | |
dc.identifier.issn | 01429612 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/64092 | |
dc.description.abstract | Drug-releasing implants delivering chemotherapeutic and radio-sensitizing agents are beginning to play a major role in the post-surgical eradication of residual glioma in the brain. Benefits from early arresting of tumor growth and tumor recovery dynamics stress the impact of drug release profiles of the implants on the efficacy of the treatment. This paper examines responses of BALB/c nude mice, bearing C6 glioma tumors subcutaneously, to treatments by PLGA microspheres, microparticles and discs-delivering Paclitaxel and Etanidazole. The experimental results are used to correlate the efficacy of treatment to in vitro release profiles from the various formulations. Our study demonstrates that radio-sensitizing effects during irradiation could be achieved by double burst profiles from Etanidazole-loaded discs, when compared to controls 17 days after implantation despite the short half-life of Etanidazole (1.4 h) in vivo. These results also showed inhibited tumor growth on tumor volumes of 59%, 65% and 70% over the blank placebo groups after 21 days of tumor growth for spray-dried microspheres, electrohydrodynamic atomization microparticles and spray-dried discs, respectively. © 2006 Elsevier Ltd. All rights reserved. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.biomaterials.2006.09.044 | |
dc.source | Scopus | |
dc.subject | Drug delivery | |
dc.subject | Etanidazole | |
dc.subject | Glioma | |
dc.subject | In vivo | |
dc.subject | Paclitaxel | |
dc.subject | Subcutaneous | |
dc.type | Article | |
dc.contributor.department | CHEMICAL & BIOMOLECULAR ENGINEERING | |
dc.description.doi | 10.1016/j.biomaterials.2006.09.044 | |
dc.description.sourcetitle | Biomaterials | |
dc.description.volume | 28 | |
dc.description.issue | 5 | |
dc.description.page | 886-894 | |
dc.description.coden | BIMAD | |
dc.identifier.isiut | 000242961200014 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.